Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TURNING POINT THERAPEUTICS, INC.

(TPTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Turning Point Therapeutics : Names New Chief Financial Officer

06/29/2021 | 09:21am EDT


ę MT Newswires 2021
All news about TURNING POINT THERAPEUTICS, INC.
09/08TURNING POINT THERAPEUTICS : Announces Early Clinical Data for Repotrectinib in ..
AQ
09/08Turning Point Therapeutics Announces Early Clinical Data for Repotrectinib in..
CI
09/01TURNING POINT THERAPEUTICS : to Participate In Upcoming Investor Conferences
AQ
08/16TURNING POINT THERAPEUTICS : Initiates Phase 1b/2 Study of Repotrectinib, Tramet..
MT
08/16TURNING POINT THERAPEUTICS : Initiates TRIDENT-2 Clinical Study Investigating Re..
AQ
08/16Turning Point Therapeutics Initiates TRIDENT-2 Clinical Study Investigating R..
CI
08/12TURNING POINT THERAPEUTICS : Receives FDA Fast Track Designation for Investigati..
MT
08/11TURNING POINT THERAPEUTICS : Granted Sixth Regulatory Designation for Repotrecti..
AQ
08/11Turning Point Therapeutics Granted Sixth Regulatory Designation for Repotrect..
CI
08/10SECTOR UPDATE : Health Care Stocks Fade Late, Finish in the Red
MT
More news
Analyst Recommendations on TURNING POINT THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 30,4 M - -
Net income 2021 -222 M - -
Net cash 2021 981 M - -
P/E ratio 2021 -17,4x
Yield 2021 -
Capitalization 3 857 M 3 857 M -
EV / Sales 2021 94,6x
EV / Sales 2022 474x
Nbr of Employees 201
Free-Float 96,4%
Chart TURNING POINT THERAPEUTICS, INC.
Duration : Period :
Turning Point Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TURNING POINT THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 78,06 $
Average target price 153,30 $
Spread / Average Target 96,4%
EPS Revisions
Managers and Directors
Athena Countouriotis President, Chief Executive Officer & Director
Paolo Tombesi Executive VP, Chief Financial & Accounting Officer
Mark J. Alles Chairman
Siegfried Reich Chief Scientific Officer & Executive VP
Mohammad Hirmand Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
TURNING POINT THERAPEUTICS, INC.-35.94%3 857
GILEAD SCIENCES, INC.22.91%89 785
BIONTECH SE340.60%86 750
REGENERON PHARMACEUTICALS34.93%67 775
WUXI APPTEC CO., LTD.35.75%60 418
VERTEX PHARMACEUTICALS-20.33%48 850